Overview

• The PRODI Center and betaSENSE have identified misfolded alpha-synuclein in cerebrospinal fluid as a reliable biomarker for early Parkinson's diagnosis.
• The patented immuno-infrared sensor (iRS) technology directly detects protein misfolding, achieving sensitivity and specificity metrics exceeding 90%.
• Findings were validated in two independent clinical cohorts totaling 134 participants from research centers in Bochum and Kassel, Germany.
• The biomarker offers potential for therapeutic monitoring, enabling researchers to measure treatment effects in clinical trials targeting Parkinson's disease.
• Results, published in EMBO Molecular Medicine on April 25, 2025, mark a significant step toward integrating this diagnostic tool into clinical workflows.